Genekor

What Genekor does

Genekor Medical S.A. is a Greek-headquartered molecular diagnostics laboratory founded in 2007 that operates accredited molecular biology and histopathology facilities in Gerakas (Athens) and Thessaloniki, providing clinical genetic testing services to healthcare providers across 47+ countries in Europe, the Middle East, Africa, Central Asia, and North America. The company's test menu is organized into four therapeutic verticals — oncology, cardiovascular, neurology, and pharmacogenomics — and comprises over 25 branded assays including comprehensive NGS panels (HerediGENE, Com.PI.it DX, prime DX), liquid biopsy platforms (prime DX Liquid, Signatera ctDNA, Avantect for pancreatic and ovarian cancer), single/biomarker tests (BRCA, MSI, PD-L1, TMB), whole-exome sequencing (MyWES), inherited cardiovascular panels (Cordis DX, MyThrombogene), neurological panels (Cerebrum DX), and pharmacogenomic assays (Warfarin, Clopidogrel, Thiopurine, Siponimod). Underlying technology centers on next-generation sequencing, biomarker identification, and bioinformatics pipelines, with samples processed in CAP- and ISO-certified labs and results delivered through a secure online provider portal supplemented by pre- and post-test genetic counseling.

The business model is a sales-led, fee-for-service B2B laboratory testing operation. Tests are ordered by oncologists, cardiologists, neurologists, and other specialists via the online portal; pricing is quote-based and not publicly disclosed; revenue is recognized per test. Genekor's GTM is anchored on direct healthcare-provider relationships, scientific publication at major oncology and genetics congresses (ESMO, ASCO, ESHG, SABCS), and referral-based sample flow from clinics and hospitals. The company holds strategic distribution/technology relationships with Exact Sciences (Oncotype DX) and Natera (Signatera), reselling or co-offering these third-party proprietary tests as part of its oncology menu. Genekor is privately held, has 51–100 employees, reports no disclosed revenue or funding history, and operates without an identified parent company or institutional investor base.

Name

Genekor

Legal name

Genekor Medical S.A.

Website

https://genekor.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Genekor is a Greek CAP-accredited molecular diagnostics lab founded in 2007 that offers NGS-based genetic tests across oncology, cardiology, neurology, and pharmacogenomics to healthcare providers in 47+ countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Molecular diagnostics services
• Genetic testing laboratory
• Cancer genomic profiling
• Precision medicine diagnostics
• Pharmacogenomic testing

Headquarters

HQ city

Athína

HQ country

Greece

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Genetic Testing Services: Laboratory testing services for cancer, cardiovascular, neurological diseases and pharmacogenomics. Revenue is generated through per-test fees billed to healthcare providers, clinics, and patients. Tests include comprehensive panels, single-gene tests, and specialized assays.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Genekor operates accredited molecular biology and histopathology laboratories that provide genetic and molecular diagnostic testing services. Its offerings span oncology panels (Oncotype DX, HerediGENE, prime DX, Signatera, BRCA), cardiovascular panels (Cordis DX, MyThrombogene, iGenome), neurological panels (Cerebrum), pharmacogenomic tests (Warfarin, Clopidogrel, Thiopurine, Siponimod), whole exome sequencing, genetic counseling, and pathology lab services. Tests are processed in-house using next-generation sequencing, liquid biopsy, and bioinformatics, and are ordered by healthcare providers through an online portal with results delivered electronically.

Product overview

Genekor is a multinational precision medicine company operating since 2007 that provides molecular genetics and immunohistopathology laboratory services. The company's product portfolio consists of specialized genetic tests organized into five main categories: (1) Cancer Molecular Tests including Oncotype DX, HerediGENE, Com.PI.it DX panels for multiple cancer types, prime DX (tissue and liquid biopsy platforms), Signatera ctDNA testing, and BRCA testing; (2) Cardiovascular Tests including Cordis DX, MyThrombogene, and iGenome; (3) Neurological Disease Tests including Cerebrum; (4) Pharmacogenomic Tests covering Warfarin, Clopidogrel, Thiopurine, and Siponimod; and (5) Supporting services including Genetic Counseling and Pathology Lab. The company uses next-generation sequencing technology and operates accredited laboratories in Europe offering diagnostic services for early detection, diagnosis, prognosis, and personalized treatment selection across oncology, cardiology, neurology, and pharmacogenomics.

Differentiator

Problem solved

Functional benefit

Brands

• Oncotype DX®: Breast cancer molecular test for recurrence score assessment
• HerediGENE®
• Com.PI.it DX®
• prime DX®
• prime DX® Liquid
• prime DX® Combo
• Avantect®
• Avantect® Ovarian
• MyWES®
• Signatera®
• BRCA Test
• Gliogene®
• Cordis DX®
• MyThrombogene®
• Cerebrum DX®
• iGenome®
• MyTheragene®
• Pathology Lab

Products and services

• Oncotype DX Molecular diagnostic test that analyzes gene expression patterns in tumor tissue to predict recurrence risk and guide treatment decisions, particularly for breast cancer patients.
• HerediGENE Multi-gene panel testing for hereditary cancer syndromes, analyzing multiple genes associated with increased cancer risk to identify pathogenic variants.
• Com.PI.it DX Comprehensive NGS-based cancer molecular tests covering multiple cancer types including Lung, Colon, Breast, Melanoma, Prostate, Cholangiocarcinoma, and GIST, for targeted therapy selection.
• prime DX Comprehensive genomic profiling test for targeted therapy selection across multiple cancer types.
• prime DX Liquid Liquid biopsy test using next-generation sequencing to detect circulating tumor DNA for targeted therapy selection and monitoring.
• prime DX Combo Combined tissue and liquid biopsy genomic profiling for comprehensive cancer profiling.
• Avantect Blood-based test for early detection of pancreatic cancer using circulating tumor DNA analysis.
• Avantect Ovarian Blood-based ovarian cancer screening test using circulating tumor DNA analysis.
• Signatera Personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) detection and monitoring across multiple cancer types.
• BRCA Test BRCA1/2 gene testing for both hereditary (germline) and tumor (somatic) mutations to guide PARP inhibitor therapy decisions.
• MSI - Microsatellite Instability Microsatellite instability testing to identify patients who may benefit from immunotherapy.
• PD-L1 PD-L1 expression testing to guide immunotherapy treatment decisions.
• TMB - Tumor Mutational Burden Tumor mutational burden assessment to predict response to immunotherapy.
• Gliogene Genetic testing for glioma and other brain tumors using multi-gene panels.
• Single Genes Single gene testing services for targeted genetic analysis.
• Cordis DX Multi-gene panel testing for inherited cardiovascular diseases including cardiomyopathy and arrhythmia syndromes.
• MyThrombogene Thrombophilia genetic testing for inherited blood clotting disorders.

Quantifiable outcome

• Precision medicine enables more accurate, effective, and targeted treatments, improving patient outcomes and minimizing side effects

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Oncotype DXcoreTechnology or IntegrationOncotype DX breast cancer recurrence score testing offered as part of Genekor's comprehensive cancer testing portfolio. Oncoype DX is a proprietary test for breast cancer recurrence assessment.
• SignateracoreTechnology or IntegrationMinimal Residual Disease (MRD) testing for cancer monitoring offered through the Natera platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology (FoundationOne CDx) — represents the upper bound of competition for Genekor's prime DX tissue and liquid biopsy profiling offerings.
• NeoGenomics: US oncology-focused clinical laboratory offering molecular and genetic testing services (including solid tumor NGS and hereditary cancer panels) to hospitals and oncologists — comparable to Genekor's oncology-heavy product mix.
• Natera: US molecular diagnostics company owning Signatera (MRD) and other oncology tests; both a partner (Genekor distributes Signatera) and a competitor in the broader precision oncology testing market.
• Synlab: One of Europe's largest medical diagnostic services providers, operating hundreds of labs across the continent with a broad portfolio including molecular genetics and oncology — a much larger incumbent in the same regional market.

Direct peers

• Invitae: US-based medical genetics company offering hereditary cancer, cardio, neuro, and PGx panels with international shipping — comparable multi-specialty genetic testing platform targeting clinicians and patients.
• Eurofins Genomics: European molecular biology services provider (part of Eurofins Scientific) offering Sanger/NGS sequencing, genotyping, and pharmacogenomic assays to researchers and clinicians — a direct competitor in the European molecular testing market.
• Centogene: Germany-headquartered rare disease and genetic diagnostics laboratory offering NGS panels, whole exome sequencing, and pharmacogenomics to providers across 100+ countries — directly comparable to Genekor in multi-vertical molecular diagnostics serving clinicians globally.
• Dante Labs: European whole-genome and exome sequencing company offering direct-to-consumer and clinician-ordered genetic tests, including hereditary cancer panels — overlapping with Genekor's MyWES and HerediGENE offerings.
• Blueprint Genetics: Specialty clinical genetics laboratory (acquired by Quest Diagnostics) focused on hereditary disease panels across cardiology, neurology, and oncology — overlapping closely with Genekor's HerediGENE, Cordis DX, and Cerebrum DX offerings.
• Medicover Genetics: European diagnostics network providing genetic and molecular testing across reproductive health, hereditary cancer, and pharmacogenomics — comparable multi-vertical specialty lab with European footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCKC7sMFecVBY-OZAlRBHNzA
• Facebookfacebook.com/genekorbiotechnology
• LinkedInlinkedin.com/company/genekor-sa
• Instagraminstagram.com/genekor_greece/?hl=el
• Xx.com/Genekor_Medical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genekor